Home > Oncology > ASCO 2019 > Head and Neck Cancer > Ado-trastuzumab emtansine a potential new treatment option for HER2-amplified advanced salivary gland cancer

Ado-trastuzumab emtansine a potential new treatment option for HER2-amplified advanced salivary gland cancer

Presented By
Dr Bob T. Li, Memorial Sloan Kettering Cancer Centre, USA
Conference
ASCO 2019
Medical writer: Kara Nyberg, PhD Ado-trastuzumab emtansine, the antibody-drug conjugate more commonly known as T-DM1, demonstrated robust activity in HER2-amplified salivary gland cancer (SGC) within a phase II basket trial, warranting further investigation in this disease (Abstract 6001). Among the 10 patients with SGC treated with T-DM1, nine obtained an objective response, six of which were complete responses. The median duration of response and median progression-free survival have yet to be reached despite a median follow-up of 12 months (range: 4 to 20 months). To gain ground in this rare malignancy, researchers are capitalizing on the targetable mutations offered up by the diverse molecular landscape of SGC. HER2 gene amplification identified through next-generation sequencing (NGS) occurs in 8% of patients with SGC and approximately 30% of patients with the aggressive salivary duct carcinoma histologic subtype.1 B...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on